Medindia
Medindia LOGIN REGISTER
Advertisement

Anpac Bio Wins Global Precision Medicine Industry Award: 2017 'Most Promising Cancer Screening Company'

Monday, July 17, 2017 Drug News
Advertisement
International life sciences leader Anpac Bio-Medical Science Company has developed breakthrough, proprietary, "Cancer Differentiation Analysis" technology that effectively reinvents cancer screening and early detection. Anpac's proprietary CDA medical devices analyze simple, standard, non-invasive "Blood Biopsies" - resulting in measurably greater early cancer detection sensitivity and specificity, with no harmful side effects in patients. The proven results of 25,000 cases to date demonstrate CDA's research validity achieving an average sensitivity and specificity rate range of 75%-90% for ten different types of cancer -- often identifying the type and location of threatening, diseased cancer cells before they form into tumors. (PRNewsFoto/Anpac Bio-Medical Science Co.)

Sponsored Post and Backlink Submission


Latest Press Release on Drug News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close